{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:00:27Z","timestamp":1779310827421,"version":"3.51.4"},"reference-count":284,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.numecd.2021.04.028","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T08:07:49Z","timestamp":1639642069000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)"],"prefix":"10.1016","volume":"32","author":[{"given":"Giulio","family":"Marchesini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Miele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Alisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Vajro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Svegliati-Baroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Letizia","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Colli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2021.04.028_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0002","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0007","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.20689","article-title":"Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town","volume":"41","author":"Pendino","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0008","first-page":"77","article-title":"Association of non-alcoholic fatty liver disease and cardiometabolic risk factors with early atherosclerosis in an adult population in Southern Italy","volume":"53","author":"Caserta","year":"2017","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.numecd.2021.04.028_bib0009","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/liv.13743","article-title":"Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population","volume":"38","author":"Petta","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.04.028_bib0010","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000087295","article-title":"Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy","volume":"49","author":"Colicchio","year":"2005","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00592-012-0406-1","article-title":"Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society","volume":"50","author":"Soresi","year":"2013","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","article-title":"Prevalence of and risk factors for hepatic steatosis in Northern Italy","volume":"132","author":"Bellentani","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0014","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF03347199","article-title":"Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome","volume":"28","author":"Marchesini","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.numecd.2021.04.028_bib0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0016","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0018","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2931985","article-title":"The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes","volume":"2016","author":"Forlani","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.numecd.2021.04.028_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/CS20130036","article-title":"Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes","volume":"125","author":"Targher","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.numecd.2021.04.028_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2017.10.023","article-title":"Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients","volume":"135","author":"Giorda","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2021.04.028_bib0022","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.diabet.2016.04.002","article-title":"Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon?","volume":"42","author":"Targher","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0023","doi-asserted-by":"crossref","first-page":"E526","DOI":"10.1503\/cmaj.092144","article-title":"Newly diagnosed diabetes mellitus as a risk factor for serious liver disease","volume":"182","author":"Porepa","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.numecd.2021.04.028_bib0024","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jhep.2016.01.014","article-title":"Type 2 diabetes and risk of hospital admission or death for chronic liver diseases","volume":"64","author":"Wild","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0026","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diabet.2019.11.003","article-title":"Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD","volume":"46","author":"Sun","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0027","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0028","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","volume":"30","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0031","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0032","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.numecd.2016.06.011","article-title":"The association of lean and fat mass with all-cause mortality in older adults: the cardiovascular health study","volume":"26","author":"Spahillari","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0033","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0034","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","article-title":"Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?","volume":"33","author":"Bhatia","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2021.04.028_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0036","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0037","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0038","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0039","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0040","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of fatty liver and risk of incident diabetes","volume":"98","author":"Sung","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0041","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2337\/dc15-0140","article-title":"Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes","volume":"38","author":"Yamazaki","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0042","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2021.04.028_bib0043","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0044","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0045","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.04.028_bib0046","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0047","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0048","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0049","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"Younes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0051","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0052","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0053","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0054","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0055","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0056","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0057","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Lu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0058","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver","volume":"112","author":"Feldman","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0059","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","article-title":"In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not","volume":"62","author":"Younossi","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2021.04.028_bib0060","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jhep.2010.09.037","article-title":"Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity","volume":"54","author":"Fracanzani","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0061","article-title":"Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease","volume":"146","author":"Dela Cruz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0062","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstrom","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.numecd.2021.04.028_bib0063","series-title":"Manuale metodologco per la Produzione di Linee Guida di Pratica Clinica. Roma: ISS - Istituto Superiore di Sanit\u00e0","year":"2020"},{"key":"10.1016\/j.numecd.2021.04.028_bib0064","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12961-018-0320-2","article-title":"The GRADE Evidence to Decision (EtD) framework for health system and public health decisions","volume":"16","author":"Moberg","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.numecd.2021.04.028_bib0066","series-title":"GRADEpro guideline development tool","year":"2020"},{"key":"10.1016\/j.numecd.2021.04.028_bib0067","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0068","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2021.04.028_bib0069","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2021.04.028_bib0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0071","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0072","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cgh.2017.08.024","article-title":"Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis","volume":"16","author":"Verhaegh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.numecd.2021.04.028_bib0073","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/bmjdrc-2020-001174","article-title":"Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels","volume":"8","author":"Zheng","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0074","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0076","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0077","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0078","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0079","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0080","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0081","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2021.04.028_bib0082","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0083","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.numecd.2021.04.028_bib0084","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0085","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14309\/ajg.0000000000000153","article-title":"Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease","volume":"d114","author":"Petta","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0086","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/liv.13549","article-title":"Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease","volume":"38","author":"Joo","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.04.028_bib0087","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/liv.13739","article-title":"Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease","volume":"38","author":"Bertot","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.04.028_bib0088","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0089","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0090","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/apt.15529","article-title":"Direct comparison of the specialised blood fibrosis tests fibrometer(V2G) and enhanced liver fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres","volume":"50","author":"Guillaume","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0091","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease","volume":"68","author":"Wong","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2021.04.028_bib0092","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0093","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0094","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/hep.27844","article-title":"The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease","volume":"62","author":"Petta","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0095","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.28843","article-title":"Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values","volume":"65","author":"Petta","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0096","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/apt.14529","article-title":"Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement","volume":"47","author":"Karlas","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0097","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0098","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28394","article-title":"Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy","volume":"63","author":"Cassinotto","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0099","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","article-title":"Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD","volume":"46","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0100","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/liv.12584","article-title":"The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"35","author":"Petta","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.04.028_bib0101","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2017.01.003","article-title":"A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis","volume":"66","author":"Boursier","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0102","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0103","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0104","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.cgh.2018.11.030","article-title":"Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease","volume":"17","author":"Hagstrom","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128774","article-title":"Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis","volume":"10","author":"Sebastiani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2021.04.028_bib0107","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD)","volume":"54","author":"Onnerhag","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0108","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease","volume":"65","author":"Boursier","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0109","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/apt.14990","article-title":"Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease","volume":"48","author":"Munteanu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0111","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/liv.14301","article-title":"Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease","volume":"40","author":"Shili-Masmoudi","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.numecd.2021.04.028_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease","volume":"19","author":"Petta","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0113","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstrom","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0114","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2013.12.009","article-title":"A population-based study on the prevalence of NASH using scores validated against liver histology","volume":"60","author":"Hyysalo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0116","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0117","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0118","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.2174\/1381612825666190119113836","article-title":"Genetics of nonalcoholic fatty liver disease: a 2018 update","volume":"24","author":"Valenti","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.numecd.2021.04.028_bib0119","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0121","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jhep.2014.12.028","article-title":"Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance","volume":"62","author":"Anstee","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0122","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2021.04.028_bib0123","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/tpj.2017.45","article-title":"The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro","volume":"18","author":"Pillai","year":"2018","journal-title":"Pharmacogenom J"},{"key":"10.1016\/j.numecd.2021.04.028_bib0124","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/jgh.14894","article-title":"Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease","volume":"35","author":"Liu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0125","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2013.09.015","article-title":"Body mass index in childhood and adult risk of primary liver cancer","volume":"60","author":"Berentzen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0127","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006998","article-title":"Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen school health records register","volume":"5","author":"Zimmermann","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2021.04.028_bib0128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2016.03.019","article-title":"Overweight in late adolescence predicts development of severe liver disease later in life: a 39years follow-up study","volume":"65","author":"Hagstrom","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.20543","article-title":"Chronological development of elevated aminotransferases in a nonalcoholic population","volume":"41","author":"Suzuki","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2014.08.041","article-title":"Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy","volume":"62","author":"Wong","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0131","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/hr.2010.45","article-title":"Fatty liver incidence and predictive variables","volume":"33","author":"Tsuneto","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.numecd.2021.04.028_bib0132","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0133","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/oby.2010.254","article-title":"Cognitive-behavioral treatment of non-alcoholic fatty liver disease: a propensity score-adjusted observational study","volume":"19","author":"Moscatiello","year":"2011","journal-title":"Obesity"},{"key":"10.1016\/j.numecd.2021.04.028_bib0134","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Fatty Liver Italian N. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0136","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0137","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2018.07.013","article-title":"An internet-based approach for lifestyle changes in patients with NAFLD: two-year effects on weight loss and surrogate markers","volume":"69","author":"Mazzotti","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0138","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0139","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.13860","article-title":"Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis","volume":"45","author":"Vilar-Gomez","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0141","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.04.028_bib0142","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0143","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cld.2009.07.006","article-title":"Lifestyle modification as the primary treatment of NASH","volume":"13","author":"Neuschwander-Tetri","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0144","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.gastro.2015.06.015","article-title":"Weight loss for a healthy liver","volume":"149","author":"Marchesini","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0145","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2174\/1381612826666200204095401","article-title":"Lifestyle changes for the treatment of nonalcoholic fatty liver disease \u2013 a 2015-19 update","volume":"26","author":"Petroni","year":"2020","journal-title":"Curr Pharma Des"},{"key":"10.1016\/j.numecd.2021.04.028_bib0146","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023597","article-title":"Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study","volume":"9","author":"Vilar-Gomez","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2021.04.028_bib0147","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0148","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clnu.2013.08.014","article-title":"Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease","volume":"33","author":"Kontogianni","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.numecd.2021.04.028_bib0149","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0151","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2009.05.033","article-title":"Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome","volume":"51","author":"Abid","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0152","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/hep.22525","article-title":"Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study","volume":"48","author":"Zelber-Sagi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0153","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2015.07.010","article-title":"Relationship of sitting time and physical activity with non-alcoholic fatty liver disease","volume":"63","author":"Ryu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0154","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"St George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0156","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1586\/17474124.2015.1075392","article-title":"The benefits of exercise for patients with non-alcoholic fatty liver disease","volume":"9","author":"Keating","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0157","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/gutjnl-2013-305718","article-title":"Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals","volume":"63","author":"Sookoian","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2021.04.028_bib0158","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2012.03.024","article-title":"Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Dunn","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.30170","article-title":"Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study","volume":"69","author":"Chang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0160","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.30867","article-title":"Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis","volume":"71","author":"Chang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0161","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","article-title":"Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis","volume":"16","author":"Ajmera","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0162","doi-asserted-by":"crossref","first-page":"876","DOI":"10.14309\/ajg.0000000000000607","article-title":"Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: A nne-year cohort study","volume":"115","author":"Xu","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0163","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1053\/j.gastro.2017.08.012","article-title":"Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease","volume":"153","author":"VanWagner","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0164","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"Aberg","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hep.30226","article-title":"Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study","volume":"70","author":"Hajifathalian","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0166","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0167","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","article-title":"The Diabetes Prevention Program (DPP): description of lifestyle intervention","volume":"25","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0168","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"RR","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0169","doi-asserted-by":"crossref","first-page":"e60495","DOI":"10.1371\/journal.pone.0060495","article-title":"Long-term effect of bariatric surgery on liver enzymes in the Swedish obese subjects (SOS) study","volume":"8","author":"Burza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2021.04.028_bib0170","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications","volume":"311","author":"Sjostrom","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.04.028_bib0171","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0172","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0173","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sjostrom","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.04.028_bib0174","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1200111","article-title":"Bariatric surgery versus conventional medical therapy for type 2 diabetes","volume":"366","author":"Mingrone","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0175","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00125-015-3591-y","article-title":"Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study","volume":"58","author":"Sjoholm","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2021.04.028_bib0176","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.28958","article-title":"Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis","volume":"65","author":"Klebanoff","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0177","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0178","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0179","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0180","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0181","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0182","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0183","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial","volume":"54","author":"Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0184","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jceh.2012.10.010","article-title":"A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis","volume":"2","author":"Sharma","year":"2012","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0185","doi-asserted-by":"crossref","first-page":"e9270","DOI":"10.5812\/hepatmon.9270","article-title":"The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial","volume":"13","author":"Razavizade","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.numecd.2021.04.028_bib0186","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0187","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.28960","article-title":"Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges","volume":"65","author":"Musso","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0188","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/liv.14385","article-title":"Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes","volume":"40","author":"Yen","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.04.028_bib0189","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.04.028_bib0190","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0191","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.04.028_bib0192","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","article-title":"The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis","volume":"58","author":"Billington","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2021.04.028_bib0193","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2021.04.028_bib0194","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/hep.25887","article-title":"Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis","volume":"56","author":"Mahady","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0196","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"key":"10.1016\/j.numecd.2021.04.028_bib0197","first-page":"3924","article-title":"Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0198","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0199","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0200","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.297.8.842","article-title":"Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis","volume":"297","author":"Bjelakovic","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.04.028_bib0201","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials","volume":"341","author":"Schurks","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2021.04.028_bib0202","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.04.028_bib0203","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","article-title":"Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis","volume":"4","author":"Dufour","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0204","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0205","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0206","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0207","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.04.028_bib0208","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.04.028_bib0209","series-title":"Intercept pharmaceuticals: update on intercept\u2019s NDA submission to the FDA","year":"2020"},{"key":"10.1016\/j.numecd.2021.04.028_bib0210","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0211","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0212","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.04.028_bib0213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","article-title":"Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease","volume":"22","author":"Omer","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0214","first-page":"OC19","article-title":"Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease","volume":"10","author":"Rana","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.numecd.2021.04.028_bib0215","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0216","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0217","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0218","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MEG.0000000000000780","article-title":"Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease","volume":"29","author":"Deng","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0219","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0220","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0221","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0222","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2021.04.028_bib0223","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0224","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Frossing","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0225","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"key":"10.1016\/j.numecd.2021.04.028_bib0226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.numecd.2021.04.028_bib0227","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0228","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0229","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2021.04.028_bib0230","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0231","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.04.028_bib0232","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2021.04.028_bib0233","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0234","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0236","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.numecd.2021.04.028_bib0237","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0238","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2021.04.028_bib0239","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0241","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cgh.2013.09.023","article-title":"Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0242","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International Liver Transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0243","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0244","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0245","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.114.009278","article-title":"Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study","volume":"130","author":"An","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0246","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/lt.25012","article-title":"Coronary artery disease in decompensated patients undergoing liver transplantation evaluation","volume":"24","author":"Patel","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.numecd.2021.04.028_bib0247","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/TP.0000000000001710","article-title":"Incidence of and risk assessment for adverse cardiovascular outcomes after liver transplantation: a systematic review","volume":"101","author":"Konerman","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0248","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/lt.24987","article-title":"Cardiac function, a key component in evaluation for liver transplant","volume":"24","author":"Yotti","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.numecd.2021.04.028_bib0249","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00007890-199503270-00010","article-title":"The prevalence of coronary artery disease in liver transplant candidates over age 50","volume":"59","author":"Carey","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0250","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/lt.500020604","article-title":"Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation","volume":"2","author":"Plotkin","year":"1996","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.numecd.2021.04.028_bib0251","first-page":"1633","article-title":"Prognostic implications of combined prone and supine acquisitions in patients with equivocal or abnormal supine myocardial perfusion SPECT","volume":"44","author":"Hayes","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.numecd.2021.04.028_bib0252","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.transproceed.2008.05.069","article-title":"Microvascular autonomic dysfunction may justify false-positive stress myocardial perfusion imaging in patients with liver cirrhosis undergoing liver transplantation","volume":"40","author":"Senzolo","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.numecd.2021.04.028_bib0253","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and de novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0254","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1161\/CIR.0000000000000105","article-title":"2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"130","author":"Fleisher","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0255","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0256","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/jhep.2002.30318","article-title":"Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0257","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/TP.0000000000002483","article-title":"Recommendations for management and treatment of nonalcoholic steatohepatitis","volume":"103","author":"Ratziu","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.numecd.2021.04.028_bib0258","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12881","article-title":"The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US","volume":"40","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0259","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0260","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.soard.2013.02.013","article-title":"Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates","volume":"9","author":"Lin","year":"2013","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0261","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.soard.2007.12.009","article-title":"Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation","volume":"4","author":"Takata","year":"2008","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.numecd.2021.04.028_bib0262","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s11695-017-2854-8","article-title":"The role of bariatric surgery in abdominal organ transplantation-the next big challenge?","volume":"27","author":"Dziodzio","year":"2017","journal-title":"Obes Surg"},{"key":"10.1016\/j.numecd.2021.04.028_bib0263","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-6143.2012.04318.x","article-title":"Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease","volume":"13","author":"Heimbach","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.numecd.2021.04.028_bib0264","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0265","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.04.028_bib0266","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0267","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","article-title":"Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease","volume":"155","author":"Ajmera","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0268","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/jlts.2002.36740","article-title":"One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation","volume":"8","author":"Ryan","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.numecd.2021.04.028_bib0269","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0270","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0271","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","article-title":"Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions","volume":"68","author":"Loomba","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0272","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0273","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0274","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0275","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/jgh.14150","article-title":"Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?","volume":"33","author":"Chan","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0276","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0277","series-title":"Principles and practice of screening for disease","author":"Wilson","year":"1968"},{"key":"10.1016\/j.numecd.2021.04.028_bib0278","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0279","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in non-alcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.04.028_bib0280","doi-asserted-by":"crossref","first-page":"i3139","DOI":"10.1136\/bmj.i3139","article-title":"The spectrum effect in tests for risk prediction, screening, and diagnosis","volume":"353","author":"Usher-Smith","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2021.04.028_bib0281","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S2468-1253(16)30205-9","article-title":"Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review","volume":"2","author":"Harris","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0282","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.3399\/bjgp18X699377","article-title":"GPs\u2019 experiences and perceptions of early detection of liver disease: a qualitative study in primary care","volume":"68","author":"Standing","year":"2018","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.numecd.2021.04.028_bib0283","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.numecd.2021.04.028_bib0284","doi-asserted-by":"crossref","first-page":"m4747","DOI":"10.1136\/bmj.m4747","article-title":"Management of non-alcoholic fatty liver disease","volume":"372","author":"Petroni","year":"2021","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1016\/j.numecd.2023.01.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000}}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:18:06Z","timestamp":1656937086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":284,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0939475321002210"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.04.028","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}